The development of resistance against chemotherapy remains one of the major challenges in the clinical management of leukemia. There is still limited insight into the molecular mechanisms that maintain the chemotherapy-resistant phenotype, despite the obvious clinical relevance that such knowledge would have. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is less pronounced. Importantly, the overexpression of Hh pathway components induces chemoprotection and inhibition of the pathway reverts chemoresistance of Lucena-1 cells, apparently by interfering with P-glycoprotein-dependent drug resistance. Our data thus identify the Hh pathway as an essential component of multidrug resistance (MDR) myeloid leukemia and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia.
Introduction
Intrinsic and acquired multidrug resistance (MDR) against chemotherapy remains a major challenge in the management of cancer in general and of leukemia in particular. Several potential molecular or cellular mechanisms responsible for MDR have been elucidated. Alterations in DNA repair, defective regulation of apoptotic gene expression, enhanced intracellular drug detoxification and overexpression of membrane drug transport proteins (for example, P-glycoprotein; P-gp) are all contributing mechanisms leading to MDR (Higgins, 2007) . However, despite our increased understanding of MDR, current treatment options are still limited. This is at least to a certain extent because of the fact that the fundamental molecular events driving the MDR phenotype of leukemic cells remain obscure. The characterization of signaling pathways sustaining the MDR phenotype is therefore of utmost importance and such knowledge would be useful for designing rational novel therapies for MDR cancers.
The Hedgehog (Hh) signaling pathway is complex and entails two cellular receptors, that is, patched-1 (Ptch-1) and smoothened (Smo) . Under unligated conditions, Ptch1 represses Smo, thereby silencing the Hh signaling pathway. Binding of the ligand (Sonic Hedgehog, Indian Hedgehog or Desert Hedgehog) to Ptch-1 alleviates Ptch-1-mediated inhibition of Smo, thereby initiating an intracellular signaling cascade leading to the activation and nuclear translocation of Gli transcription factors (Dean, 1997; Bijlsma et al., 2006; Zhao et al., 2007; .
Hh signaling, originally characterized as part of the morphogenetic code, is critical for growth and differentiation during embryogenesis (Dean, 1997; Bijlsma et al., 2006; Zhao et al., 2007; . However, Hh more recently emerged as a signaling system that remains active in adulthood, in which it mediates tissue regeneration and remodeling, hematopoietic homeostasis and T-cell maturation; however, as a downside, Hh has emerged as a critical mediator in various forms of oncogenesis. Interestingly, Hh signaling seems important in normal stem cell self-renewal, as abnormal Hh expression or deficient Ptch-1 activity leads to a pre-malignant stem cell displaying unrestrained local proliferation (Dean et al., 2005; Dierks et al., 2008) . Moreover, the Hh pathway seems to be essential in the survival and expansion of BcrAbl þ leukemic stem cells (Dierks et al., 2008) . In line with these findings, Zhao and colleagues (Zhao et al., 2009) recently showed that Hh signaling has an important role in hematopoietic stem cell self-renewal and in maintenance of cancer stem cells in leukemia, although the loss of Hh signaling through conditional deletion of Smo in the adult hematopoietic compartment had no apparent effect on adult hematopoiesis in mice (Hofmann et al., 2009) , warranting further studies as to its actual role in the hematopoietic compartment. Together, these considerations prompt further investigation into the potential role of the Hh pathway in the pathophysiology of leukemic disease.
Various lines of evidence suggest that Hh might function in leukemia to promote chemoresistance. It has previously been shown that Hh signaling induces resistance to radiotherapy and an MDR phenotype in esophageal adenocarcinomas (Sims-Mourtada et al., 2006) . In apparent agreement, a significant upregulation of Hh and Gli-1 expression was observed in the majority of residual solid tumors after chemoradiotherapy, suggesting that Hh signaling contributes to chemotherapy resistance in such tumors. Whether the Hh pathway has a similar role in leukemia remains elusive, and this study therefore aimed at deciphering the potential role of Hh in chemotherapy resistance in leukemia. To this end, we compared Hh pathway activity in chemotherapy-sensitive parental K562 cells and in MDR-resistant Lucena-1 daughter cells (Rumjanek et al., 2001) . We established that Hh signaling maintains the chemoresistant phenotype in an apparently P-gpdependent manner and propose that Hh inhibition might be an attractive treatment strategy to revert (or prevent) chemoresistance in myeloid leukemia.
Results
Sensitivity to chemotherapeutic drugs of K562 and Lucena-1 cells Studying therapy-induced drug resistance in vitro remains a challenge, but Lucena-1 cells have previously been described as vincristine-resistant leukemia cells derived from vincristine-sensitive K562 parental cells (Rumjanek et al., 2001) ( Figure 1) ; indeed, in our hands, the microtubule polymerization inhibitor vincristine, as well as other therapeutically important drugs such as the DNA intercalating mitoxantrone and doxorubicin, efficiently kills K562 cells, whereas these drugs only minimally affect Lucena-1 survival ( Figure 1a) . Chemoresistance of Lucena-1 was accompanied by upregulation of drug transporters P-gp and MRP-1, (Figure 1b ) whereas the P-gp inhibitor verapamil partially reverted drug resistance. We concluded that the comparison of K562 and Lucena-1 constitutes a valid model to study induced resistance for classical chemotherapy. 
Different sensitivity to chemotherapeutic drugs is determined by the Hh pathway
We decided to study whether activation of Hh signaling is a characteristic of chemoresistance under our experimental conditions. Importantly, as shown in Figure 2a , the bona fide Hh target gene Gli1 displays sevenfold increased mRNA levels in Lucena-1 cells, compared with the chemosensitive parental line, whereas Sufu expression levels (which are suggested to be inversely associated with Hh signaling (Sva¨rd et al., 2006) , although this is not generally established) were reduced by twofold. At the protein level, we observed that Sonic Hedgehog was induced, together with the classical Hh target genes Gli and Ptch-1, in chemoresistant cells ( Figure 2b ). Finally, nuclear extracts showed the hallmark appearance of full-length Gli1 in the nuclei of chemoresistant cells, but not in those of chemosensitive cells ( Figure 2c ). Overall, these data show that the chemotherapy-resistant phenotype is accompanied by a constitutively activated Hh signaling pathway.
The Hh pathway maintains the multidrug-resistant phenotype To investigate the importance of Hh signaling in chemoresistance, K562 cells were transfected with SmoM2-GFP (a constitutively active Smo variant) or GFP-overexpressing constructs. The transfections were effective (efficiency of approximately 40% (data not shown)) and resulted in increased Gli1 and Ptch-1 expression levels ( Figure 3a ). As shown in Figure 3b , induction of Hh signaling by SmoM2 overexpression protected K562 leukemia cells from vincristine treatment. Furthermore, vincristine treatment increased the percentage of SmoM2-GFP-positive cells, but not that of GFP-only transfected cells (Figure 3c ), suggesting that Hh pathway activity might be an important component in the acquisition of resistance to classical chemotherapy in leukemia.
Pharmacological inhibition of Hh signaling reverts resistance in Bcr-Abl þ cells We observed that chemoresistance was accompanied by induction of Hh signaling and that activation of Hh signaling is sufficient for acquiring chemoresistance; however, therapeutically, it is more interesting to investigate to which extent the chemoresistant phenotype actually depends on activation of this pathway. Thus, we pharmacologically inhibited the Hh pathway in Lucena-1 cells and analyzed the effect on chemoresistance. As shown in Figure 4a , Hh pathway inhibitors cyclopamine (Chen et al., 2002) and vitamin D3 (Bijlsma et al., 2006) indeed inhibited Hh pathway activity in Lucena-1 cells (using Ptch-1 levels as read out). Importantly, both Hh inhibitors did not affect cell survival per se in concentrations up to 10 mM (Figure 4b ). The presence of Hh inhibitors, however, substantially enhanced the sensitivity of Lucena-1 cells to vincristine to levels not markedly different from those of the parental line (IC 50 approximately 10 nM in both cases; compare Figures 1 and 4c ). This effect was not restricted to microtubules system-targeted chemotherapy, as doxorubicin-or mitoxantrone sensitivity was also restored to the levels of the parental cell line following inhibition of the Hh pathway.
To provide further proof for the notion that inhibition of the Hh pathway may revert chemoresistance, Lucena-1 cells were treated with vincristine in combination with Gant61 (inhibitor of Gli1 transcriptional activity) . As shown in Figure 4d , Gant61 efficiently inhibited Hh pathway activity and the inhibition of Gli1 transcriptional activity by Gant61 indeed reverses chemoresistance, suggesting that the increased level of Gli1 (Figure 2a ) is important to maintain the resistant phenotype in Lucena-1 cells. To determine whether the effect of Hh inhibition is specific for MDR leukemia cells, the combinations mentioned above (Hh pathway inhibitors plus vincristine) were also tested in K562 cells. As shown in Figure 4e , Hh inhibitors hardly effected vincristine-induced cell death (at least in comparison with the effect observed in Lucena-1 cells (Figure 4c) , suggesting that the chemosensitization induced by Hh pathway inhibitors is specific for MDR cells. Overall, it seems that pharmacological inhibition of the Hh pathway might constitute an interesting opportunity for chemosensitization in the management of MDR myeloid leukemic disease.
Myeloid specificity of chemosensitization by inhibition of Hh signaling
To address the specificity of the effects observed, a more or less random panel of leukemia cells and solid cancers was exposed to pharmacological Hh inhibition, and effects of this treatment on chemosensitivity were assessed. As evident from Figure 5 , neither solid cancers nor T-cell leukemia showed much evidence for such chemosensitization. Although these results show that alleviation of therapy resistance using Hh inhibitors is restricted to the myeloid compartment, they also provide good evidence that effects observed are specific and cannot be explained from an off-action of the pharmacological inhibitors involved.
Pharmacological inhibition of Hh signaling interferes with P-gp expression
Subsequently, we were interested as to whether we could dissect the point of interaction of Hh signaling with the classical cellular physiology of leukemic cell. As Hh appears to affect the resistance of MDR leukemia cells, we hypothesized that targeting the Hh pathway might reduce P-gp levels. As shown in Figure 6 , all Hh inhibitors indeed reduced expression levels of P-gp, although to different extents.
Discussion
Intrinsic and acquired MDR against chemotherapy remains one of the major problems in the management of leukemic disease (Martelli et al., 2003; O'Hare et al., 2006; Sims-Mourtada et al., 2006; Diehl et al., 2007; Lo¨wenberg, 2007) . The majority of leukemia patients (75%) of o60 years do present an initial complete remission after chemotherapy. However, 60% of these responders will ultimately present disease relapse, usually occurring within the first 2 years after the start of treatment (Lo¨wenberg, 2007) . Despite our increased understanding of MDR and the elucidation of several underlying mechanisms (Dean et al., 2005; Higgins, 2007; Kroemer and Pouyssegur, 2008) , treatment options are still limited. The characterization of signaling pathways sustaining MDR is thus essential for designing rational novel therapies for MDR leukemia. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with the activation of Hh signaling, that overexpression of Hh pathway components induces chemoprotection and that inhibition of the pathway reverts chemoresistance of Lucena-1 cells. Our data thus identify the Hh pathway as an essential component of MDR leukemia, and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia. These data provide a mechanistic explanation as to the previous observation that inhibition of the Hh pathway in Kasumi1, -3 and TF1 myeloid cell lines increased sensitivity to suboptimal doses of the antimetabolite cytarabine (Kobune et al., 2009) . We propose that activation of the Hh pathway is both sufficient and essential for resistance to classical chemotherapy in myeloid leukemia.
The mechanism of action of Hh inhibitors is probably dependent on its effect on P-gp expression levels (as shown in Figure 6 ). This immediately explains that the chemosensitization induced by Hh inhibitors in combination with vincristine is only observed in Lucena-1 cells and is not (very) effective in K562 or GLC4-doxo cells. These latter cells express MRP-1, but not P-gp, and sensitization can consequently not be induced in these cells by Hh inhibitors that target P-gp. Overall, these data indicate an important role of the Hh pathway in the maintenance of the MDR phenotype in myeloid leukemias.
Our findings might be relevant for the treatment of MDR leukemia, but in addition, our data may be relevant for the early detection of resistance. Indeed, the expression of sentinel markers (for example, Ptch-1) of activation of the Hh pathway in peripheral blood myeloid leukemia cells may be an indication that a patient is developing chemoresistance and is possibly a useful predictor of treatment failure, necessitating the switch to alternative therapy. Further studies are obviously essential to address the validity of these latter points.
Materials and methods
Compounds, antibodies, constructs and cell lines Vitamin D3, cyclopamine, mitoxantrone, daunorrubicin and vincristine were obtained from Sigma (St Louis, MO, USA). Gant61 was obtained from Alexis (La¨ufelfingen, Switzerland). Polyclonal antibodies against Gli1 and Ptch-1 were purchased from Cell Signaling (Beverly, MA, USA). Antibodies against Smo, a-tubulin and b-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), whereas the monoclonal anti-P-glycoprotein antibody was obtained from Sigma. 5E1 Shh-blocking antibody was obtained from the Developmental Hybridoma Bank (Iowa City, Iowa, USA). K562, U-937, Jurkat, KG1a, ACHN and PC3 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA), Lucena-1 cells were kindly donated by Professor Vivan Rumjaneck, GLC4-doxo cells were obtained from the oncology laboratory of the University of Groningen (The Netherlands). SmoM2-GFP in pMES was a generous gift from Dr Eberhart.
Cell culture and transfections Cells were cultured in RPMI supplemented with non-essential amino acids and 10% fetal calf serum according to routine cell culture procedures. Transfections were performed using Amaxa Cell Line Nucleofector Kit V (VCA-1003) from Lonza Cologne AG (Cologne, Germany) according to the manufacturer's directions. Briefly, cells were transfected with SmoM2-GFP (5 mg DNA/1 Â 10 6 cells) or GFP (2.5 mg DNA/1 Â 10 6 cells) expression vectors. Next, transfected cells were placed in RPMI 0.5% fetal calf serum for 16 h, and subsequently treated with vincristine for 48 h and analyzed by fluorescence-activated cell sorting or MTT assays. For reversion assays, cells were treated with mitoxantrone, doxorubicin, vincristine or imatinib, in combination with cyclopamine (10 mM), vitamin D3 (10 mM) or Gant61 (5 mM).
Cell viability assay Cells (3 Â 10 4 ) were seeded in flat-bottom 96-well plates treated with the indicated concentrations of drugs. During the last 2 h, 0.5 mg/ml thiazolyl blue tetrazolium bromide (MTT) was added (Mosmann, 1983) . After incubation, the supernatant was discarded; cells were lysed in 100 ml of 0.1N HCl in isopropanol and absorbance was measured at 570 nm in a Figure 6 Hh pathway inhibitors sensitize Lucena-1 cells dependent on P-glycoprotein expression. P-glycoprotein expression in Lucena-1 cells was analyzed after 24 h of treatment with cyclopamine, vitamin D3 and Gant61. Shown on the left is a representative experiment, whereas the quantification of three independent experiments is shown on the right (mean ± s.e.m.).
Benchmark Plus Microplate Spectrophotometer (Bio-Rad, Hercules, CA, USA).
Quantitative reverse transcription-PCR After RNA isolation according to routine procedures, quantitative PCRs detecting the expression level of different proteins and GAPDH were performed. hP-gp-F 5
0 . Standards consisted of dilutions of RNA from K562 and Lucena-1.
Nuclear extract preparation
Nuclear extracts were prepared according to routine procedures. Briefly, 2 Â 10 7 cells were harvested and washed twice with ice-cold phosphate-buffered saline and resuspended in 0.2 ml of ice-cold cell extract buffer (10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl 2 , 10 mM KC1, 0.5 mM dithiothreitol and 0.2 mM phenylmethysulfonyl fluoride ). Cells were kept on ice for 10 min to allow them to swell, mixed by vortex for 10 s and centrifuged at 4 1C at 14 000 g for 30 . The supernatant was discarded, and the pellet was resuspended in 30 ml of nuclear extraction buffer (20 mM HEPES-KOH (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgC1 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol and 0.2 mM phenylmethysulfonyl fluoride), placed on ice for 20 min and centrifuged at 4 1C at 14 000 g for 2 min. The remaining supernatant was used as nuclear extract in western blotting assays.
Western blotting analysis Cells (2.5 Â 10 7 ) were lysed in 200 ml of lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Tween-20, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM O-Vanadate, 1 mM NaF and protease inhibitors (1 mg/ml aprotinin, 10 mg/ml leupeptin and 1 mM 4-(2-amino-ethyl)-benzolsulfonyl-fluoride-hydrochloride)) on ice for 2 h. Protein extracts were cleared by centrifugation and the protein concentration was determined using the Lowry method (Hartree, 1972 ). An equal volume of 2 Â SDS gel loading buffer (100 mM Tris-HCl (pH 6.8), 200 mM dithiothreitol, 4% SDS, 0.1% bromophenol blue and 20% glycerol) was added and samples were boiled for 10 min. Cell extracts were resolved by SDS-PAGE (12%) and transferred to polyvinylidene difluoride membranes. Membranes were blocked in 1% fat-free dried milk or bovine serum albumin (2%) in TBS/0.05% Tween-20 and incubated overnight at 4 1C with appropriate primary antibody at 1:1000 dilutions. After washing in TBS/0.05% Tween-20, membranes were incubated with antirabbit, antigoat and antimouse horseradish peroxidase-conjugated secondary antibodies at 1:2000 dilutions in blocking buffer for 1 h. Blots were imaged using LumiLight Plus ECL (Roche, Basel, Switzerland) on a LAS-3000 imaging system.
Statistical analysis
Unless otherwise indicated, all experiments were conducted in triplicate and the results shown in the graphs represent the mean and s.e. Data were analyzed by ANOVA. Western blots represent three independent experiments.
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